The Impact of Lorazepam on Cognition in APOE e4 Carriers

Completed · Not applicable · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

We expect the results of this pilot study to justify a larger study that follows people to determine if certain tests of memory and attention, performed while sleepiness is induced by a single dose of lorazepam (a widely used anti-anxiety medication) could predict an individual's risk of developing AD. We plan to compare cognitively normal people who possess a common gene that increases risk for AD- the apolipoprotein E (APOE) e4 allele-to individuals without this gene. We hypothesize that a single 2 mg dose of lorazepam will cause more cognitive impairment in carriers of the APOE e4 allele than in noncarriers, and that the carriers will recover more slowly from these impairments than noncarriers.

Key facts

Study ID

NCT00586430

Run by

Mayo Clinic

People needed

36

Starts

2005-12-01

Expected to finish

2007-07-01

Last updated by the study team

2008-01-04

Who can join

Age: 50 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• a score of at least 28 on the MMSE
• a score of less than 10 points on the HAM-D-17
• age 50-65
• genotype APOE e3/e4 or APOE e4 non-carriers
• cognitively normal

You may not qualify if…

• significant medical, psychiatric, or neurological illnesses
• use of benzodiazepines within the previous four weeks
• currently using sedating antihistamines

Where it is running

• Mayo Clinic — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.